Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 17/20 | 0.64 |
| ▸ | MME | P08473 | 1/20 | 0.59 |
| ▸ | CTSK | P43235 | 4/20 | 0.54 |
| ▸ | MMP12 | P39900 | 1/20 | 0.54 |
| ▸ | MMP13 | P45452 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CTSH | P09668 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.51 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.49 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21985830 | 0.87 | CTSC (0.64) | CTSCCTSKKCNH2LTB4RLTB4R2 | |
| SCHEMBL16932288 | 0.87 | CTSC (0.64) | CTSCCTSKKCNH2LTB4RLTB4R2 | |
| SCHEMBL2074657 | 0.83 | CTSC (0.57) | CTSCMMECTSKMMP12MMP13 | |
| SCHEMBL2074655 | 0.83 | CTSC (0.57) | CTSCMMECTSKMMP12MMP13 | |
| SCHEMBL1499323 | 0.82 | CTSC (0.72) | CTSCCTSKKCNH2 | |
| SCHEMBL1499321 | 0.82 | CTSC (0.72) | CTSCCTSKKCNH2 | |
| SCHEMBL2884861 | 0.82 | CTSC (0.61) | CTSCMMECTSKKCNH2LTB4R | |
| SCHEMBL2076519 | 0.80 | CTSC (0.64) | CTSCMMECTSKKCNH2 | |
| SCHEMBL2889507 | 0.80 | CTSC (0.81) | CTSCMMECTSKCYP1A2CYP3A4 | |
| SCHEMBL2889502 | 0.80 | CTSC (0.81) | CTSCMMECTSKCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201581-A1 | Novel Compounds 010 | ASTRAZENECA AB (SE) | 2011-08-18 | — | — | US | disclosed |
| US-7902181-B2 | Compounds 010 | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | disclosed |
| EP-2231597-A1 | PEPTIDYL NITRILES AND USE THEREOF AS DIPEPTIDYL PEPTIDASE I INHIBITORS | AstraZeneca AB (SE) | 2010-09-29 | — | — | EP | disclosed |
| US-20090306042-A1 | Novel Compounds 010 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| WO-2009074829-A1 | PEPTIDYL NITRILES AND USE THEREOF AS DIPEPTIDYL PEPTIDASE I INHIBITORS | ASTRAZENECA AB (SE) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306042-A1 | Novel Compounds 010 | MRGPRX2, F12, TBXA2R | CTSC 3209/4885MME 2522/4885CTSK 3280/4885 |
| US-20110201581-A1 | Novel Compounds 010 | MRGPRX2, F12, TBXA2R | CTSC 3209/4885MME 2522/4885CTSK 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.